UNSPSC 51422111: Clocortolone acetate

This classification denotes a therapeutic glucocorticoid C24H30ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85061HTR8T, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-chloro-6-fluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as clocortolone acetate, which bears US NIH Compound Identifier 3037082. Most nations, for tariff and trade purposes, schedule clocortolone acetate under HS 29372200 and SITC 54153.

As of Q4 2014, CLOCORTOLONE ACETATE remains US FDA's Preferred Term for this commodity. Clocortolone acetate bears US NLM identifiers UMLS ID C0770567 and NCI Concept Code C77410. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C)C)O)CL)C)F.

UNSPSC 51422111 Clocortolone acetate is a Commodity code nominally covering a specific topical corticosteroid pharmaceutical, but recent state and local opportunities tagged under it show minimal alignment with the code's narrow product scope. The only substantially documented recent opportunity involves Seminole County, Florida's procurement of Naloxone and drug deactivation systems through an IFB, which targets emergency response and harm-reduction supplies rather than dermatological pharmaceuticals. A second opportunity—a Request for Information from the Texas Health and Human Services Commission regarding direct-to-manufacturer prescription programs—addresses pharmacy benefit infrastructure and contracting models, not the acquisition of specific pharmaceutical products. The mismatch between the code's nominal scope and the actual work being solicited suggests either miscoding at the issuing body or that this Commodity code sees limited genuine activity in state and local procurement. Practitioners should verify that opportunities tagged under this code align with their product or service lines before investing in response preparation.

Activity under UNSPSC 51422111 is sparse and geographically scattered. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, represents the only direct procurement of tangible goods; the Texas HHS Commission's RFI (HHS0017013), issued April 3, 2026, is exploratory and does not commit to any purchase. No repeat buyers, established contracting patterns, or concentrated demand emerge from available records. The absence of recent solicitations under this code across major pharmaceutical procurement venues or health system networks suggests minimal state and local market activity. Firms should monitor whether this code experiences increased use as state and local health systems expand prescription programs, but the current signal does not support active pursuit based on recent opportunities.